secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001193125-25-122511
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic TX45 Phase 1b in PH-HFpEF shows 19% PCWP reduction, sustained 29-day effects
--------------------------------------------------------------------------------

- Single IV dose of TX45 reduced PCWP by 19.0% [95% CI, -26.1% to -11.9%] in 19-patient cohort.
- In CpcPH subgroup (PVR≥2), PVR decreased 32.0% (≥2) and 35.5% (≥3); 30%+ reduction in PVR.
- Echocardiogram showed sustained improvements in TAPSE/SPAP and RVFAC for 29 days post-dose.
- Cardiac output increased 18.5% overall; greater improvement in patients with higher baseline PVR.
- No serious or severe adverse events; Phase 1b Part B in HFrEF topline expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525122511/0001193125-25-122511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525122511/d939029d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-122511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer